StockTipsArenaBeta

SELL Dr. Reddy's Laboratories Limited — Deven Mehata, IDBI Capital Markets and Securities

SELLDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byDeven Mehata, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))8 Oct 2026via CNBC Awaaz.

Entry₹1,190.6Inferred
Target₹1,140
Total upside +4.25%
Stop loss₹1,205-1.21% risk
CMP₹1,1803h ago
Active+0.89%+3.39%upside left 14d left
Follow Deven Mehata for new calls(12% target hit, 78 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 194 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 8 Oct, 7:53 pm IST
2 supporting6 opposing
Supports the SELL call (2)

Dr. Reddy's faces securities fraud probe after Q1 earnings hit by semaglutide batch issues.

NewsGoogle News·25 Sept · 2w ago

(opens in new tab)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NewsGoogle News·25 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the SELL call (6)

MACD above its signal line — bullish momentum

Technicals · macd·8 Oct · today

Citi raises target for Dr Reddy's Laboratories stock to INR 1,450

NewsGoogle News·2 Oct · 6d ago

(opens in new tab)

Dr. Reddy's Laboratories stock gets a Citi upgrade to Buy

NewsGoogle News·1 Oct · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories stock gets a Citi upgrade as margins face a test

NewsGoogle News·30 Sept · 1w ago

(opens in new tab)

Hikma signs exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories for Nicotinell across MENA

NewsGoogle News·28 Sept · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Deven Mehata, IDBI Capital Markets and Securities

Every call and its outcome